News
LAB
2.380
-2.86%
-0.070
Weekly Report: what happened at LAB last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at LAB last week (0212-0216)?
Weekly Report · 02/19 09:19
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Standard BioTools Inc.'s price-to-sales ratio of 7.1x is higher than most companies in the Life Sciences industry. The company's revenue growth is expected to outshine the industry in the coming years. However, the company's revenues have fallen 17% in the last year. Standard BioTools is trading at a high P/S compared to the industry.
Simply Wall St · 02/17 13:59
Weekly Report: what happened at LAB last week (0205-0209)?
Weekly Report · 02/12 09:17
Standard BioTools And Navignostics Announce Collaboration Agreement To Advance Imaging Capabilities In Personalized Medicine
Standard BioTools announced a collaboration agreement with Navignostics AG for development of clinical research applications and services. The Hyperion XTi™ Imaging System is a significant advancement in clinical research. The system will be used to generate and differentiate biological insights to help in the fight against cancer.
Benzinga · 02/07 13:39
Weekly Report: what happened at LAB last week (0129-0202)?
Weekly Report · 02/05 09:19
Weekly Report: what happened at LAB last week (0122-0126)?
Weekly Report · 01/29 09:18
Weekly Report: what happened at LAB last week (0115-0119)?
Weekly Report · 01/22 09:18
STANDARD BIOTOOLS INC: [Amend]Current report
Press release · 01/19 22:16
STANDARD BIOTOOLS INC: Securities to be offered to employees in employee benefit plans
Press release · 01/19 22:16
STANDARD BIOTOOLS INC: Registration statement under Securities Act of 1933
Press release · 01/19 22:16
Standard BioTools files to sell 38.43M shares for holders
Standard BioTools files to sell 38.43M shares for holders Jan. 19, 2024. Standard BioTools filed a prospectus related to the proposed resale of 38. 43M shares of its common stock by selling stockholders. The company expects to sell the shares.
Seeking Alpha · 01/19 22:14
Weekly Report: what happened at LAB last week (0108-0112)?
Weekly Report · 01/15 09:18
STANDARD BIOTOOLS INC: [Amend]General statement of acquisition of beneficial ownership
Press release · 01/12 20:28
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?
Standard BioTools Inc. (NASDAQ:LAB) has US$64.6m of debt on its balance sheet. The company made a loss of US$76m over the last year. Despite this, it has net cash of $64.3m. Standard BioTools is a company with a history of losing money. The balance sheet is a good indicator of a company's ability to manage its debt. Standard bioTools has 3 warning signs it should be watched for.
Simply Wall St · 01/12 11:09
STANDARD BIOTOOLS INC: Statement of changes in beneficial ownership of securities
Press release · 01/10 04:07
STANDARD BIOTOOLS INC: Statement of acquisition of beneficial ownership by individuals
Press release · 01/10 00:19
More
Webull provides a variety of real-time LAB stock news. You can receive the latest news about STANDARD BIOTOOLS INC through multiple platforms. This information may help you make smarter investment decisions.
About LAB
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Its segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. It provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company distributes its systems through its direct sales force and support organizations.